General Information:

Id: 11,778 (click here to show other Interactions for entry)
Diseases: COVID-19
Diabetes mellitus, type II - [OMIM]
Insulin resistance
Mammalia
review
Reference: Hussain A et al.(2020) COVID-19 and diabetes: Knowledge in progress Diabetes Res. Clin. Pract. 162 [PMID: 32278764]

Interaction Information:

Comment Considering that ACE2 is a functional receptor for SARS-CoV-2 and its levels can be increased by ACEIs and ARBs, it has been argued that these drugs might affect negatively the outcome of COVID-19 patients. On the contrary, some have advocated that ACEIs and ARBs might rather be beneficial. SARS-CoV infection and the virus Spike protein reduce ACE2 expression. Mice injected with SARS-CoV Spike presented worsened acute lung failure, which could be attenuated by blocking the renin-angiotensin pathway. Nevertheless, a retrospective analysis performed on 112 patients with COVID-19 and CVD did not show a significant difference in the proportion of ACEI/ARB medication between survivors and non-survivors.
Formal Description
Interaction-ID: 116654

drug/chemical compound

Angiotensin II type 1 receptor blocker

increases_quantity of

gene/protein

ACE2

Drugbank entries Show/Hide entries for ACE2